Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Cancer immunotherapy Stories

2012-03-06 12:07:57

Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells. It is the first time a system for making an adaptable, engineered T-cell to attack specific tumor types has been proposed, depending on which abnormal proteins, called antigens, are expressed by individual patients´ tumor cells. For now, the system is being refined in experiments using healthy...

2012-03-06 10:41:07

Silencing it impairs tumor growth, making ROR1 a potential therapeutic target A team of scientists at the University of California, San Diego Moores Cancer Center has identified a novel protein expressed by breast cancer cells — but not normal adult tissues — that could provide a new target for future anti-cancer drugs and treatments. Led by Thomas J. Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research and Interim Director of the UC San Diego Moores Cancer...

2012-02-29 08:24:00

BETHESDA, Md., Feb. 29, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that its COO, Anthony Maida III, Ph.D., MA, MBA, will be presenting at the Cancer Immunotherapy Conference as the lead afternoon speaker at 1:45 pm ET on Wednesday, February 29, 2012, in Boston, Massachusetts at the Metro Meeting Center at 101 Federal Street. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) Dr. Maida's presentation, entitled "Developing...

2012-02-27 08:30:00

WORCESTER, Mass. and TORONTO, Feb. 27, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) announced today that Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., will give a presentation at the upcoming Cancer Immunotherapy Summit to be held in Boston, MA February 27-29. The presentation, entitled "Recent Advances in Understanding the Immune System and the Role of Th cells," will be given Wednesday, February 29 at 9:45 am EST. The...

2012-02-13 05:01:00

SAN DIEGO, Feb. 13, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the...

2012-02-09 10:45:10

DNA sequences from tumor cells can be used to direct the immune system to attack cancer, according to scientists at Washington University School of Medicine in St. Louis. The research, in mice, appears online Feb. 8 in Nature. The immune system relies on an intricate network of alarm bells, targets and safety brakes to determine when and what to attack. The new results suggest that scientists may now be able to combine DNA sequencing data with their knowledge of the triggers and targets...

2012-02-01 07:00:00

WORCESTER, Mass. and TORONTO, Feb. 1, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines. A number of products developed with this technology are currently in clinical development. The patent helps to secure the novel Antigen Express vaccine technology platform in the...

2012-01-27 10:49:26

The findings were published online in Cancer Research Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumors. The discovery has been patented and there are plans to develop the vaccine for clinical use...

2012-01-23 10:44:09

The work will be published in the latest issue of Nature Medicine journal Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer. This new mechanism is a mutation in an oncogene called EGFR (epidermal growth factor receptor) causing resistance to treatment using a drug called cetuximab, a monoclonal antibody which specifically attacks the EGFR. The study proves that, both in lab models and...

2012-01-17 08:30:00

WORCESTER, Mass. and TORONTO, Jan. 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a detailed interview conducted at the BioTech Showcase 2012 during last week's JPMorgan Healthcare Conference in San Francisco with Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., regarding the Antigen Express breast cancer vaccine, is available on the Stock News Now website (www.stocknewsnow.com) and on the Generex...